Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 21, 2026, titled "Orbicular s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic® (Semaglutide Injection), supported by OneSource as CDMO partner".
Onesource Specialty Pharma Limited Press Release Apr 21 2026
Earlier from Onesource Specialty Pharma
- Press Release Feb 11 2026
- Press Release Nov 11 2025
- Inseego and National MSP OneSource Join Forces to Tackle the Growing 5G FWA Market Opportunity
- Press Release Aug 04 2025